未知生产厂商
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Auto-immune diseases are indicated where an individual's immune system mistakenly attacks the body's own tissues. PN0621 works by blocking the action of TNF (tumour necrosis factor) which is involved in this attack.
Intended for the treatment of auto-immune diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
